The Chemotherapy Induced Neutropenia Market is growing steadily due to the rising global prevalence of cancer and the increasing demand for supportive care medications. Chemotherapy often suppresses bone marrow function, leading to neutropenia, a condition marked by low white blood cell counts and increased infection risk. As cancer treatment rates rise across breast, lung, colorectal, and ovarian cancers, the need for preventive and therapeutic neutropenia drugs is expanding. Advances in colony-stimulating factors (CSFs) and long-acting biologics are improving patient outcomes and reducing hospitalization rates.

What Is the Chemotherapy Induced Neutropenia Market Size and Forecast?

The global Chemotherapy Induced Neutropenia Market size was valued at USD 651.26 Million in 2025 and is projected to grow at a CAGR of 3.58%, reaching approximately USD 925.79 Million by 2035. Growth is supported by increasing adoption of granulocyte colony-stimulating factor (G-CSF) therapies, improved access to oncology care, and the development of biosimilars that enhance treatment affordability.

Chemotherapy Induced Neutropenia Market Share by Drug Type and Application

The Chemotherapy Induced Neutropenia Market share is segmented by drug type into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Among these, G-CSF holds the largest share due to its widespread clinical use and strong efficacy in reducing infection risk.

By application, breast cancer and lung cancer account for significant market contributions, followed by colorectal and ovarian cancers. These segments represent high chemotherapy utilization rates, thereby increasing demand for neutropenia management therapies.

Request sample report Explore

Chemotherapy Induced Neutropenia Market Trends and Regional Insights

Key Chemotherapy Induced Neutropenia Market trends include the rising adoption of biosimilars, long-acting injectable formulations, and research into novel myeloid growth factors. Hospital pharmacies dominate the distribution channel segment, while online pharmacies are gradually gaining traction. Hospitals and cancer research institutes remain the primary end users.

Regionally, the United States leads the market due to advanced oncology infrastructure and high cancer incidence rates. The EU-4 and the United Kingdom, Japan, and China also represent significant growth opportunities due to expanding cancer treatment programs.

Major companies operating in the market include Novartis AG, Lupin Limited, Baxter International, Teva B.V., BeyondSpring Pharmaceuticals, G1 Therapeutics, and Spectrum Pharmaceuticals.